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Abstract:
Although tumour recurrence is an important and not infrequent event in meningiomas, predictive
immunohistochemical markers have not been identified yet. The aim of this study was to address this clinically
relevant problem by systematic retrospective analysis of surgically completely resected meningiomas with and
without recurrence, including tumour samples from patients who underwent repeat surgeries. Three established
immunohistochemical markers of routine pathological meningioma work-up have been assessed: the
proliferative marker Ki-67 (clone Mib1), the tumour suppressor gene p53 and progesterone receptor (PR). All
these proteins correlate with the tumour WHO Grade, however the predictive value regarding recurrence and
progression in tumour grade is unknown.
Hundred and fourteen surgical specimens of 70 meningioma patients (16 male and 54 female) in a 16 years
interval have been studied. All tumours had apparently complete surgical removal. On Mib1, PR and p53
immunostained sections the percentage of labelled tumour cells, the staining intensity and the multiplied values
of these to parameters (the histoscore) was calculated. Results were statistically correlated with tumour WHO
Grade, (sub)type, recurrence and progression in WHO Grade at subsequent biopsies. 
Our results confirmed previous findings that the WHO Grade has strong forward proportion to Mib1 and p53
and an inverse proportion to the PR immunostain. We have demonstrated that Mib1 and p53 have significant
correlation with and predictive value of relapse/recurrence irrespective of histological subtype of the same
WHO grade. As a quantitative marker Mib1 has best correlation with percentage of labelled cells, whereas p53
with intensity & histoscore.
In conclusion, the immunohistochemical panel of PR, p53, Mib1 in parallel with applying standard diagnostic
criteria based on H&E stained sections is sufficient and reliable to predict meningioma recurrence in surgically
completely resected tumours.
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Introduction
Meningioma is one of the most frequent brain tumours [9]. According to the 
World Health Organization (WHO) classification there are several subtypes, like 
meningothelial, fibrous, transitional, psammomatous, angiomatous, microcystic, 
secretory, lymphoplasmacyte rich, metaplastic, choroid, clear cell, rhabdoid, papillary 
and other rare morphological phenotypes [6,21]. The assigned WHO Grade I-III. 
reflects the probable prognosis which is determined by the subtype and/or specified 
morphological features such as mitotic rate, presence or absence of small 
geographic necrosis, nucleus-cytoplasm ratio an others [21]. Although tumour 
recurrence is important and not infrequent event, our knowledge on predisposing 
factors is rather limited. The risk of recurrence increases with the WHO grade being 
7-25% in WHO grade I, 30-50% in WHO grade II and 50-95% in WHO grade III 
[27,28,32,33], respectively. The extent of resection assessed by the Simpson 
Grading System influences recurrence rates which is one reason of the wide range of 
probability [30]. Simpson Grading System classify the completeness of removal in a 
5-tier scale ranging from macroscopically complete removal (grade I) to simple 
decompression with or without biopsy (grade V). Skull irradiation, inherited mutation 
of the NF2 gene (Neurofibromatosis type 2) and epigenetic factors may also 
predispose to recurrence [22,23]. 
Another important phenomenon is tumour progression to higher WHO Grade. 
However, the risk and probability of progression remains rather unpredictable – even 
less so than tumour recurrence. Hence, there is growing clinical need to identify 
additional and better predictors for recurrence and tumour progression than the 
currently used histological grade and extent of resection. Because 
immunohistochemistry has been routinely used in the pathological diagnostic practice 
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for decades, the search for predictive immunohistochemical markers is of 
importance. In our study we focussed on 3 well known immunohistochemical markers 
in routine pathological work-up of meningioma: the proliferative marker Ki-67 (clone 
Mib1), the tumour suppressor gene p53 and progesterone receptor. All these proteins 
have been studied in meningioma and the correlation with tumour grade have been 
confirmed by several studies. However, the predictive value regarding recurrence 
and progression in tumour grade remains unknown. The aim of this study is to 
address these clinically relevant questions by a systematic retrospective analysis of 
meningiomas with and without recurrence, with special emphasis on tumour samples 
from patients who underwent repeat surgeries due to tumour recurrence.
p53 is one of the major tumour suppressor proteins. The physiological functions 
of p53 are cell cycle regulation and conserve the stability of the genome by 
preventing mutations, therefore it is called ‘the guardian of the genome’[17]. More 
than 50 percent of human tumours carries deletion or mutation of the p53 genes 
(TP53) [13]. p53 can be activated by DNA damage, oxidative stress, osmotic shock, 
ribonucleotide depletion or oncogene expression. The activation is marked by an 
increase in the half-life of p53 and a change of its conformation [16] therefore shows 
increased LI with immunohistochemistry with the polyclonal antibodies routinely used 
in tumour diagnostics. The anticancer activity of p53 works through several 
mechanisms: it activates DNA repair proteins, induces growth arrest at the G1/S 
regulation point through p21 or initiates apoptosis if the DNA damage is irreversible 
[12]. It has been investigated also in meningioma and several studies showed 
positive correlation with grade, and tumour recurrence [4,7,8,14,15,24,26], whereas 
authors reported the grade as an independent predictive factor of recurrences with 
high Mib1 and p53 LI being supportive marker helpful in borderline cases [31]. 
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Ki-67 is necessary for cellular proliferation; it is present during all active phases 
of the cell cycle, and absent from the G0 phase. Mib1 is the usually applied clone of 
the Ki-67 antibody which is widely used as proliferative marker in the routine 
diagnostic work-up. The Mib1 LI shows a strong correlation with tumour growths, 
relapse/recurrence, length of in various tumours [2,3,34] including meningioma 
[18,19].
Progesterone receptor (PR) is a steroid hormone receptor. It has been 
demonstrated that meningioma cells show positivity for PRs; the ratio of the positive 
cells is inversely proportional to the WHO Grade [18,27]. Also described earlier the 
cellular biosynthesis of PR in meningioma is not oestrogen regulated as it is other 
sex steroid in tissues [5,7]. PR is encoded by the PGR gene on the long arm of the 
chromosome 11. In physiological situation after binding the progesterone hormone 
the receptor undertake a dimerization and is transported to de nucleus to binding to 
the DNA and inducing transcription. Both form (progesterone receptor A and 
progesterone receptor B) has a regulatory domain, DNA binding domain, a hinge 
section and a ligand binding domain, but only the PR-B form possess transcription 
activation function.
The Mib1 antibody, p53 and PR are widely used immunohistochemical markers 
in meningioma diagnosis. In high-grade meningioma the Mib1 labelling index (LI) is 
higher [1,4,28,29]. In our previous study we have reported a significant correlation 
between the frequency and intensity of p53 immunostaining and WHO Grade 
[10].The reduced of PR immunoreactivity is another known feature in the high grades 
of meningioma [18,20,25].
The aim of this study is to establish an easy-to-use immunohistochemical panel 
for the routine neuropathological use, which can predict meningioma 
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relapse/recurrence. For validation we analysed the changes in immunohistochemical 
characteristics and expression patterns during relapse/recurrence and examined 
their relation to tumour grade.
Materials and methods
Hundred and fourteen surgical specimens of 70 meningioma patients (16 male 
and 54 female) in a 16 years interval have been retrospectively studied. All cases 
were revised by a consultant neuropathologist (TH) and divided into three grades and 
histological subtypes according to the WHO classiﬁcation [21].
We established two study groups: Patients with one or more 
recurrence/relapse(s) (R/R group) and patients with meningioma without any 
radiological or post mortem evidence of recurrence/relapse (non-R/R group). Only 
cases with apparently complete surgical removal and no evidence of residual tumour 
on post-operative MRI were included.
After the surgical removal tissue samples were processed to generate sections 
from formalin fixed and paraffin embedded (FFPE) blocks which were stained with 
haematoxylin-eosin (H&E). One representative tissue block was selected per case. 
From these blocks tissue micro arrays (TMAs) were build. Each TMA contained 
samples from 10 cases (three samples from each cases) plus 2 normal brain tissue 
sample in the left upper corner as reference to enable specimen identification in the 
TMA (Fig. 1.). In total 12 TMA were built, containing tissue samples from 114 
neurosurgical interventions.
Immunohistochemistry (IHC) was performed according to standardized 
methods. In brief, 4 µm thick sections from TMA blocks were stained with p53 mouse 
monoclonal antibody (clone DO-7, M7001, DAKO, Glostrup, Denmark); PR antibody 
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(NCL-PGR-312, clone 16, Novocastra, Newcastle, UK) and anti-Ki-67 antibody (clone 
Mib1, M7240, DAKO, Glostrup, Denmark) according to the manufacturers’ protocol 
with 1:100, 1:100 and 1:200 dilution for p53, PR and Ki-67, respectively. Sections 
were incubated with the primary antibody for 6 hours in room temperature; the 
visualization was performed with SuperSensitive™ One-step Polymer-HRP Detection 
System on Leica Bond Max™ fully automated IHC stainer with negative controls 
(omitting the primary antibody).
All of the H&E and immunostained TMA sections were scanned with a 
Panoramic Scanner (3DHistech, Budapest, Hungary). Two digital images were taken 
at 400x magnification from each tissue samples, in total 6 from each case. According 
to the intensity of nuclear staining of cells 4 semi quantitative scores were applied: 0 
(none), 1+ (weak), 2+ (moderate) and 3+ (strong) (Fig. 2.).
Images in 10 reference cases were analysed quantitatively with ImageJ (NIH, 
Bethesda, USA) software Cell Counter function, to determine the exact percentage of 
immunopositive cells (Fig. 3.). These images were used as reference cases to aid 
accurate semi-quantitative assessment in all cases. This is a method easily and 
reliably applicable in the routine pathological diagnostic practice, similarly to the 
assessment of percentage of immunopositive cells in other tumours. 
Not only the percentage value of immunopositive cells but also the average 
labelling intensity score (0-3+; for reference images see Fig. 2) of the staining were 
calculated in each picture. Similarly to the Histoscore of breast carcinoma i.e. the 
multiply of the percentage of the positive cells and the average intensity of the 
positive cell nuclei [11] were calculated.
Data were analysed with SPSS 22.0 for Windows (IBM, Armonk, NY, USA) 
statistical programme, using Kruskall-Wallis H-test, Mann-Whitney U-test and 
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Wilcoxon signed ranks test. The patient were grouped by the grades (65 WHO Grade 
I; 33 WHO grade II and 16 WHO Grade III) and also based on the recurrence or 
relapse (R/R group) showed up at least 5 years after resection: patients without 
recurrence or relapse (non-R/R group), patients with definitive relapse or recurrence 
(R/R group).
The non-R/R cases were WHO Grade I, while the R/R group have 18 WHO 
Grade I, 9 WHO grade II and 2 WHO Grade III tumour in the 1st histological sample. 
Ethical approval has been obtained from the Institutional Research Ethics 
Committee (Number: DEOEC RKEB: 2437-2005).
Results
The 70 patients’ average age was 56 years in the time of the first pathological 
examination. There were no significant differences between the R/R group and the 
non-R/R group. There were 16 patients (3 male and 13 female; average age 54 
years) without recurrence or relapse (non-R/R group) with at least 5 years survival 
after surgery and 31 patients (8 male and 23 female; average age 53 years, overall 
time of recurrence 19.6 months) with definitive relapse or recurrence (R/R group). 
Further 23 patients (5 male and 18 female, average age 59 years) were operated 
within 5 years without recurrence/relapse; however the time window was too short to 
include them in the non-R/R group. There were 65 WHO Grade I cases, 33 WHO 
Grade II cases and 16 WHO Grade III cases. All of the non-R/R cases were WHO 
Grade I. The R/R group contained 19 WHO Grade I, 9 WHO Grade II and tree WHO 
Grade III cases according to the 1st neuropathological diagnosis of the first surgical 
specimen. There were 8 patients whose subsequent surgical specimens had higher 
WHO Grade than the first; 15 patients whose first and last cases both showed the 
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same grade; and 6 patient who only had 1 histological samples and the 
recurrence/relapse was diagnosed by imaging techniques.
The histological subtypes were not statistically different between the R/R group 
and non-R/R group: there were 6 meningothelial, 5 transitional, 3 fibrous and 2 
psammomatous in the non-R/R group, while 9 meningothelial, 6 transitional, 3 
fibrous, one psammomatous, one clear cell, 8 atypical and 3 anaplastic in the R/R 
group. There was no increased tendency for recurrence for any WHO grade 1 
subtype. Among grade 2-3 meningiomas there was no specific subtype which had 
higher frequency of recurrence than the respective grade in general.
There is significant correlation between WHO tumour grade and Mib1 LI (%) (p 
< 0.001), Mib1 staining intensity (p=0.001), Mib1 histoscore (p<0.001), p53 staining 
intensity (p<0.001), p53 histoscore (p=0.031), PR LI (%) (p<0.001), PR intensity 
(p<0.001) and PR histoscore (p<0.001) respectively (Kruskall-Wallis test). Comparing 
only Grade I and Grade II tumours there is significant correlation with Mib1 LI (%) 
(p<0.001), Mib1 intensity (p<0.001), Mib1 histoscore (p<0.001), p53 intensity 
(p=0.001), PR LI (%) (p=0.014), PR intensity (p=0.029) and PR histoscore (p=0.013) 
respectively. Comparing Grade II and Grade III tumours there is significant correlation 
with p53 intensity (p=0.049), PR LI (%) (p=0.008), PR intensity (p=0.008) and PR 
histoscore (p=0.009) respectively. When comparing Grade I and Grade III tumours 
there is significant correlation of higher grade with increased Mib1 LI (%) (p<0.001), 
Mib1 histoscore (p<0.001), p53 intensity (p<0.001), p53 histoscore (p=0.023), PR LI 
(%) (p<0.001), PR intensity (p<0.001), PR histoscore (p<0.001) respectively (Mann-
Whitney test) (Table 1., Fig. 4.).
Irrespective of the grades of the R/R group comparing the non-R/R and R/R 
groups there are significant correlation with the Mib1 LI (%) (p<0.001), Mib1 intensity 
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(p=0.004), Mib1 histoscore (p<0.001), p53 LI (%) (p=0.027), and the WHO grade 
(p=0.003) respectively (Fig. 5.). In WHO Grade I tumours in the R/R group there are 
significant correlation with the Mib1 LI (%) (p=0.009), Mib1 histoscore (p=0.029), p53 
LI (%) (p=0.032), p53 histoscore (p=0.038) respectively (Table 2., Fig. 6.).
In the R/R groups compare the first case with the recurrent/relapsed cases 
there are significant difference between the Mib1 LI (%) (p=002), Mib1 histoscore 
(p=0.001), p53 intensity (p=0.006) and the grade (p=0.001) respectively; and with 
Wilcoxon signed rank test compared the first and last case of the same patient there 
are significant difference in the grade (p=0.007), Mib1 LI (%) (p=0.042), Mib1 
histoscore (p=0.050), and p53 LI (%) (p=0.042) respectively (Table 3., Fig.7.).
According our data the WHO grade has strong forward proportion to Mib1 and 
p53 and an inverse proportion to the PR immunostain (as shown in several previous 
papers). As a quantitative marker the Mib1 has better correlation with percentage, 
whereas p53 with intensity & histoscore. Therefore, the panel of PR, p53, Mib1 is 
sufficient to characterize meningioma immunohistochemically regarding risk of 
recurrence possible as an integral part of the routine diagnostic histopathological 
practice.
Discussion 
Meningioma is one of the most common intracranial tumour with high incidence 
in the neurosurgical practice. The histological subtypes are well characterised by the 
WHO, and the grading is based on these histological characteristics, morphological 
findings and the mitotic ratio. The Simpson Grading System also can provide further 
information of the probability of the recurrence [30]. 
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The aim of this study was to establish an easy-to-use immunohistochemical 
panel for the routine neuropathological use, which can predict meningioma 
relapse/recurrence. This is particularly relevant for tumours in problematic 
localization (e. g. falx memingiomas).
For validation we analysed the changes in immunohistochemical characteristics 
and expression patterns during relapse/recurrence and their relation to tumour grade.
Meningiomas usually are non-infiltrative neoplasms therefore complete surgical 
resection is curative. However, tumour may spread laterally in small nests in the dura 
mater which could be source of recurrence. Hence no chemotherapy is effective even 
in high grade meningiomas – radiotherapy increases malignant transformation [33]– 
another argument for discovery of relatively simple predictive markers of tumour 
progression and recurrence.
However the Mib1 labelling index can be different according which laboratory 
performed the reaction [8], in a standardized methods can help with the data 
interpretation, and comparison both in routine and experimental purpose. Accordant 
to previous studies the higher initial Mib1 LI has a predictive value regarding 
increased probability of recurrence. In R/R cases during evolution in time (i.e. time 
between 1st and last surgical procedure) there was an increase in Mib1 LI consistent 
with the known fact that tumour progression may occur over time which is reflected 
by increased proliferative potential and higher WHO grade.
The routine used p53 antibody does not separate the wild type and the mutant 
protein. Interestingly, the p53 LI and histoscore (but not the labelling intensity) has an 
inverse correlation with chance of recurrence in the WHO Grade I tumours in our 
study, but if we examine all the WHO Grades, the higher staining in the higher 
grades, change to forward proportion, similarly with the prior studies [7,14,15]. This 
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may be explained by the fact the p53 immunoreactivity does not  distinguish between 
wild type (WT) and mutant protein; in non-recurrent cases increased normal protein 
may have a beneficial effect as p53 is involved in DNA damage repair. In contrast, in 
recurrent cases p53 is more likely to be mutant and ineffective thereby contributing to 
tumour growth and recurrence. Mutation analysis could answer this problem, 
however, the focus of our study is on immunohistochemical markers, and therefore it 
is beyond the scope of the current project. Today the antibodies specific to mutated 
p53 are not routinely used therefore not applied in this study. The p53 LI and 
histoscore decreased during time to recurrence which may indicate decreased levels 
of WT protein.
PR has inverse relation with tumour grade in concert with previous reports 
[10,18,20,25] and no predictive value regarding recurrence.
Using p53 and Ki-67 molecular markers and the relatively simple and quick 
assessment method the increased risk of recurrence can be reliably predicted. 
However, it is foreseeable that the presented method has the potential for further 
improvement with the use of digitalized histological specimens, because this enables 
automated quantitative image analysis as an integral component of the diagnostic 
process.
In summary, we have demonstrated a rather simple immunohistochemistry-
based method with routinely used molecular markers to identify patients with 
increased risk of recurrence. Further work is needed to validate our work in more 
patients, multiple centres and in a prospective manner with long follow-up. The 
combination of histological, surgical and imaging markers may be a more sensitive 
tool to predict recurrence and this can also be tested in future studies.
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Table 1
Download source file (18.12 kB)
 
Table 1.:
 
Mib1
Percentage
Mib1
Intensity
Mib1
Histoscore
p53
Percentage
p53
Intensity
p53
Histoscore
PR
Percentage
PR
Intensity
PR
Histoscore
Kruskall-
Wallis ,000 ,001 ,000 ,316 ,000 ,031 ,000 ,000 ,000
Mann-
Whitney
grade I-II
,000 ,000 ,000 ,272 ,001 ,065 ,014 ,029 ,013
Mann-
Whitney
grade II-III
,449 ,320 ,831 ,654 ,049 ,376 ,008 ,008 ,009
Mann-
Whitney
grade I-III
,000 ,086 ,000 ,198 ,000 ,023 ,000 ,000 ,000
Comparison of Grade I, Grade II and Grade III cases with Kruskall-Wallis test, and 
the WHO Grade pairs with Mann-Whitney test. Immunostain percentage, intensity 
(average instensity of cells: 0, 1, 2 or 3) and Histoscore (intensity x percentage), for 
Mib1, p53 and Progesteron receptor (PR).
 
Table 2
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Table 2.:
 Grade
Mib1
Percentage
Mib1
Intensity
Mib1
Histoscore
p53
Percentage
p53
Intensity
p53
Histoscore
PR
Percentage
PR
Intensity
PR
Histoscore
Mann-
Whitney 
any 
grades
,003 ,000 ,004 ,000 ,027 ,955 ,069 ,207 ,497 ,215
Mann-
Whitney 
grade I
1,000b ,009b ,126b ,029b ,032b ,195b ,038b ,708b ,708b ,858b
Comparison of the non-recurrance/relapse (non-R/R) cases and recurrence/relapse 
(R/R) cases first surgical specimens without regarding the grade (firs row) and only in 
WHO Grade I cases (second row).
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Table 3.:
 Grade
Mib1
Percentage
Mib1
Intensity
Mib1
Histoscore
p53
Percentage
p53
Intensity
p53
Histoscore
PR
Percentage
PR
Intensity
PR
Histoscore
Mann-
Whitney 
progression
0,001 0,002 0,098 0,001 0,861 0,006 0,553 0,154 0,154 0,159
Wilcoxon 
progression
0,007 0,042 0,237 0,050 0,042 0,484 0,559 1,000 0,545 0,876
Comparison of the first and last surgical specimens of the recurrence/relapsed (R/R) 
cases with Mann-Withney test (first row) and Wilcoxon signed rank test (second row). 
Immunostain percentage, intensity (average instensity of cells: 0, 1, 2 or 3) and 
Histoscore (intensity x percentage), for Mib1, p53 and Progesteron receptor (PR).
 
Figure 1
Download source file (147.74 kB)
 
Low magnification image of histological slide stained with haematoxylin-eosin, made from tissue
microarray (TMA) paraffin block. In the upper left corner there are two tissue (brain) samples for
guidance regarding localization. The numbers from 1 to 10 represent the individual cases. Every
’donor’ case have 3 different samples in the ’recipient’ block. Scale bar 5mm.
Powered by TCPDF (www.tcpdf.org)
 
Figure 2
Download source file (510.34 kB)
 
Ki-67 (clone Mib1), p53, and progesterone receptor (PR) immunostain with representative images of
the different immunolabelling intensities: negative (0), minimal positivity (1+), medium positivity
(2+), to strong positivity (3+). Scale bar 20µm.
Powered by TCPDF (www.tcpdf.org)
 
Figure 3
Download source file (46.45 kB)
 
Ki-67 (clone Mib1), p53 and progesterone receptor (PR) immunopositive cells counted using ImageJ
programme. A, C, E, G, I, K pictures are the originals, whereas B, D, F, H, J L show cells numbered
with ImageJ Cell Counter plug-in. The numbers from 1-4 stand for the negative, 1+, 2+ and 3+ cells,
respectively. A-B pictures are immunostained for Mib1 (43,5% positivity). The C-D pictures are
immunostained for Mib1 (6,9% positive). E-F pictures are stained for p53 (58,9% positive). G-H
pictures immunostained for p53 (9,8% positive). I-J pictures stained for PR (93,9% positive). K-L
pictures immunostained for PR (31,3% positive).
Powered by TCPDF (www.tcpdf.org)
 
Figure 4
Download source file (279.53 kB)
 
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain with
Ki-67 (clone Mib1), p53 and Progesteron receptor (PR) for WHO Grade I, II and III cases.
Powered by TCPDF (www.tcpdf.org)
 
Figure 5
Download source file (176.59 kB)
 
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain with
Ki-67 (clone Mib1), and p53 for non-reccurence/relapse (non-R/R) and reccurence/relapsed (R/R)
cases, without regarding the WHO grades.
Powered by TCPDF (www.tcpdf.org)
 
Figure 6
Download source file (177.08 kB)
 
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain with
Ki-67 (clone Mib1), and p53 for non-reccurence/relapse (non-R/R) and WHO Grade I.
reccurence/relapsed (R/R) cases.
Powered by TCPDF (www.tcpdf.org)
 
Figure 7
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Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain with
Ki-67 (clone Mib1), and p53 for the 1st, 2nd and last surgical specimens of the recurrence/replase
(R/R) cases.
Powered by TCPDF (www.tcpdf.org)
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Figures
Figure 1 - Download source file (147.74 kB)
Low magnification image of histological slide stained with haematoxylin-eosin, made from tissue
microarray (TMA) paraffin block. In the upper left corner there are two tissue (brain) samples for
guidance regarding localization. The numbers from 1 to 10 represent the individual cases. Every
’donor’ case have 3 different samples in the ’recipient’ block. Scale bar 5mm.
Figure 2 - Download source file (510.34 kB)
Ki-67 (clone Mib1), p53, and progesterone receptor (PR) immunostain with representative images
of the different immunolabelling intensities: negative (0), minimal positivity (1+), medium
positivity (2+), to strong positivity (3+). Scale bar 20µm.
Figure 3 - Download source file (46.45 kB)
Ki-67 (clone Mib1), p53 and progesterone receptor (PR) immunopositive cells counted using
ImageJ programme. A, C, E, G, I, K pictures are the originals, whereas B, D, F, H, J L show cells
numbered with ImageJ Cell Counter plug-in. The numbers from 1-4 stand for the negative, 1+, 2+
and 3+ cells, respectively. A-B pictures are immunostained for Mib1 (43,5% positivity). The C-D
pictures are immunostained for Mib1 (6,9% positive). E-F pictures are stained for p53 (58,9%
positive). G-H pictures immunostained for p53 (9,8% positive). I-J pictures stained for PR
(93,9% positive). K-L pictures immunostained for PR (31,3% positive).
Figure 4 - Download source file (279.53 kB)
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain
with Ki-67 (clone Mib1), p53 and Progesteron receptor (PR) for WHO Grade I, II and III cases.
Figure 5 - Download source file (176.59 kB)
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain
with Ki-67 (clone Mib1), and p53 for non-reccurence/relapse (non-R/R) and reccurence/relapsed
(R/R) cases, without regarding the WHO grades.
Figure 6 - Download source file (177.08 kB)
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain
with Ki-67 (clone Mib1), and p53 for non-reccurence/relapse (non-R/R) and WHO Grade I.
reccurence/relapsed (R/R) cases.
Figure 7 - Download source file (185.55 kB)
Percentage (%), Intensity (0, 1+, 2+, 3+) and Histoscore (intensity x percentage) of immunostain
with Ki-67 (clone Mib1), and p53 for the 1st, 2nd and last surgical specimens of the
recurrence/replase (R/R) cases.
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